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Background: The organization for economic co-operation and development (OECD) 
member states have a high income and developed infrastructure including good preventive 
healthcare systems. The World Health Organization recommends that Human Papillomavirus 
(HPV) vaccination should be given to young girls as they believe it’s the best available 
method to reduce cervical cancer morbidity and mortality. They have formulated HPV 
vaccination policies targeting to increase coverage for young girls before sexual debut. 
Parents are key contact persons in achieving higher vaccination rates as they have to make the 
decision to consent before their under-age daughters is vaccinated. Through responses, we 
may understand the main reasons to why parents delayed or declined to accept their daughters 
to be vaccinated. The responses from parents of non-vaccinated girls will give public health 
and promotion programs the needed information. These finding may help optimize HPV 
vaccination coverage while offering protection to the population.  
Objective: To determine and identify themes, factors and barriers explaining why parents 
decide to delay or refuse to accept HPV vaccination for their daughter’s aged 9-17, through 
systematic review of qualitative and quantitative primary studies. Due to current trends in 
information source in media and internet, the researcher wanted to ascertain whether social 
media and religion plays a central role in parental decline or delay a decision on HPV 
vaccination. 
Methods: comprehensive search from several selected databases ranging from 2008 to 2016 
were done and primary sources identified followed by critical appraisal. A desire for 
combination of qualitative and quantitative articles led to the utilization of a Qualitative Meta-
summary. The method consisted of extraction, separation of findings, editing of findings, 
grouping of similar findings, abstraction and Size effect calculation. 
Results:Twenty-three studies consisting of ten quantitative and 13 qualitative were 
synthesized. A total of 15458 parents had reported HPV vaccination. There were 246 reasons 
identified (both similar and different) with a total of 31740 responses (parents had more than 
one response). The responses were categorised into twenty groups which were further 
abstracted into seven broad categories. They consisted of vaccine related, parental concerns 
and perceptions, girl child factors, general factors, provider health factors, pharmaceutical or 






Conclusion: Vaccine related responses including drug safety, unknown future adverse effect 
and doubts on the vaccine was a major reason for non-vaccination. Parental concerns, girl child 
related reasons and luck of information played a role in parental decision. The health provider, 
pharmaceutical and government related reasons adding to social media though were of less 
effect, they were part of reasons for refusal to accept HPV vaccination. Both qualitative and 
quantitative combination with Qualitative metasummary synthesis gave the review large 
response and size effect. However the similar grouped findings had both quantitative and 
qualitative articles enabling the synthesis to determine the ‘what’ and ‘why’ using both 
questionnaires and interview responses. These parental explained reasons if addressed through 
collective measures by primary public health services could contribute to decrease refusal 
hopefully increasing HPV vaccination coverage. Future research in length of protection, 
induced and natural HPV immunogenicity difference, drug efficacy comparison of Pap smear 
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High-income countries are grouped together under an Umbrella organization established in 
1961. The Organisation for Economic Co-operation and Development (OECD) member 
countries consists of 34 nations. They are characterised by high income, bigger economies, 
better healthcare, well-developed infrastructure, less population growth and good transport 
systems. The countries include Canada, Mexico and USA (North America), Chile (South 
America), Australia and New Zealand (Oceania), Japan, Israel and S. Korea (Asia) and 
Turkey. The bulk of the nation’s fall under the European Union and partners consisting of 
Austria, Belgium, Denmark and France. Others including  Germany, Greece, Iceland, Ireland, 
Italy, Luxembourg and Netherlands. Included also are Norway, Portugal, Slovenia, Spain, 
Sweden, Czech Republic, Estonia, Finland and Hungary.  Poland, Slovak Republic, 
Switzerland and United Kingdom(1, 2) 
Cervical cancer is a disease affecting the lower end of the uterus. It occurs when cervical cells 
begin to divide uncontrollably producing abnormal cells which can invade surrounding 
tissues. Metastasis occurs when cells break from the primary tumour and spreads to other 
sites. Infection with Human Papillomavirus (HPV) is strongly correlated with cervical cancer, 
and the virus is transmitted sexually (3). Cervical cancer is the outcome of persistent infection 
with HPV, which accounts for approximately 95%of  incidences (4). There are over 100 
known different types of HPV that exist (5). Among them, two types of HPV (16& 18) causes 
more than three-quarters of cervical cancers. About 75% of all females have had infections at  
particular time in their life without knowing it (6). There are no seen signs and symptoms of 
infection as it’s resolved spontaneously. Persistent infection with different types of HPV 16 
and 18 leads to pre-cancerous lesions which if untreated proceeds to progress into cervical 
cancer which is a slow process that takes many years before detection. The known risk factors 
are early age sexual initiation and multiple partners with the lack of timely screening as an 
important element in developing cervical cancer (7). A regular Pap smear screening in older 
women is used for early detection of the virus though there is no known drug for treatment 
and immune system clears the virus in most cases (3). According to WHO, Vaccination of 
young girls with HPV vaccine before sexual debut combined with screening are key in 
achieving cervical cancer and prevention (8). Currently, there exist two vaccines which 
protect against HPV 16 and 18 that accounts for 70% of all cervical cancers. Gardasil is used 
for both girls and boys while Cervarix is for girls only. Gardasil protects further from HPV 6 




2.0 GLOBAL PERSPECTIVE 
Vaccination policies against cervical cancer (HPV vaccines) have different implementation 
strategies from ages of 10-14 with some countries extending to 17 years based on age of 
sexual debut. In most European nations it is administered as part of primary healthcare and  
Parents are highly involved due to the age of uptake with consent required in most 
programs (10). 
According to European centre for disease control, Gardasil and Cervarix protects against 
HPV 16 and 18 which causes 73% of cervical cancer. This means the remaining causes of 
approximately 30% is beyond the two vaccines (11). Cervical cancer is believed to 
develop over many years within an estimated period of 10-30 years. HPV vaccine against 
cervical cancer takes a longer time before antibodies effects can be identified. The HPV 
vaccine (Gardasil) shows a five to six-year protection after vaccination. The current HPV 
vaccination schedule includes two injections within a six month period as opposed to 
previous three injections for girls aged 10-14 (12). The exact duration of HPV vaccine 
protection is still not yet known though is carefully monitored by the medical authorities. 
(12). 
2.1 CURRENT VACCINATION DETAILS. 
Based on world health organization (WHO) 2014 publication data, over 270,000 women died 
in 2012 due to cervical cancer and 528,000 new cases were detected during the year (8). 
Within the European Union, (EU) nations consisting of 29 countries (inclusive of Norway and 
Iceland though all are not OECD members) cervical cancer was the second most common 
cancer after breast cancer affecting women of ages 15–44. The current estimate indicates that 
every year there are around 33 000 cases of cervical cancer in the EU and 15 000 deaths. The 
primary cause of cervical cancer is related to persistent infection of the genital tract by a high-
risk human Papillomavirus type (12, 13). By 2010, Denmark, France, Ireland, Italy, Latvia, 
Luxembourg, the Netherlands, Norway, Portugal, Romania, Slovenia, Sweden and the United 
Kingdom had a national HPV vaccination coverage systems in place (12).  
The European Union members consisting majorly of OECD had variant coverage ranging 
from 17% to 84% for the reporting countries. Portugal (84%), the United Kingdom (80%) and 
Denmark (79%) were at the top of that range.(12). In Poland where vaccination is not tax 
funded, 3513 cases were reported with 1856 deaths in 2012 and Vaccination is at less than 
10% (14). HPV centre information for Germany indicates 4995 cervical cancer cases with 
1566 death in 2012. In Norway based on SYSVAK 2014 national HPV vaccination data 
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vaccination coverage is estimated to be 76% (15). The Norwegian cancer registry reported  
1542 cases of cervical cancer in 2012 with 330 death during the year (16). Most OECD 
members in Pacific, Asia, Americas and Europe reported cases ranging from 203 (Israel) to 
13960 (Mexico). There were reported death from cervical cancer ranging from 50 (New 
Zealand) to 4769 (Mexico). Vaccination rates ranged from less than 10% in Poland to 84% in 
Portugal. (14, 17-27). 
2.2 STUDY RATIONALE. 
Cervical cancer causes death ranging from tens to thousands of women in OECD countries. 
It’s one of the cancers with known causes associated with HPV. Preventive mechanisms 
involve cervical smear check for women above 29 years and HPV vaccination for pre-
adolescent girls (13). the vaccinations is believed to protect the girls and young woment from 
age nine untill 29 years when they are elligible for Pap smear. Most of the countries that have 
introduced HPV vaccination are from the WHO regions Americas, Europe and West Pacific 
regions which are in OECD (13, 27). The current rates of vaccination are different between 
countries. There has been a reported decline in cervical cancer within high-income countries 
as indicated by Centre for Disease control (CDC) and European Centre for Disease control 
(ECDC). The ECDC countries reported higher vaccination coverage on HPV vaccine launch 
in Europe followed by reduced uptake in different parts during the years after initial launch. 
There was great enthusiasm during the launch of HPV vaccination but by 2012 until now 
there has been a declining uptake (12). According to WHO, HPV vaccinations as part of 
national immunisation programmes for girls aged 9-13 years from countries with the 
prevention of cervical cancer should be a public health priority (8).  The initiative is feasible 
and financially sustainable, as cost-effectiveness has been evaluated. In nations with 
vaccination policy and high income, HPV vaccination is administered with parental consent 
for minors. This research intended to answer the question on reasons as to why some parents 
are declining to accept HPV vaccination for their children. Based on their experiences, are 
there common factors that will answer ‘why’ some have decided not to vaccinate?  Some 
parents obtained their information on vaccination through media. Based on research done in 
the USA on conflict of print media on HPV vaccination, it was found that there were both 
pro-vaccine and anti-vaccination coverage (28). Furthermore, there was a reported decline of 
HPV vaccination based on negative media reporting in Japan (29). Whether this affected 





2.3 STUDY BENEFITS AND JUSTIFICATION 
Singular qualitative and quantitative studies provide insights into the reasons and responses as 
to why national HPV vaccination is lower than expected in some countries. Different studies 
have indicated parental concerns leading to refusal of their daughters receiving HPV vaccine 
within the OECD countries. Through synthesizing the data from several primary qualitative 
and quantitative studies, the researcher intended to obtain a final abstracted responses from 
parents whose daughters are not vaccinated. These collective parental responses could provide 
a more comprehensive list of barriers and explanations answering ‘why’ they delayed or 
refused to vaccinate their daughters against HPV. By understanding these common barriers 
policymakers and health care providers may be able to address low HPV vaccination rates. 
This systematic review aims to add knowledge to existing literature on the topic while 
enhancing chances of future research on HPV vaccination in different parts of OECD. A 
previous qualitative review study was done on barriers and facilitators of HPV vaccination 
but did not consider developed nations with HPV vaccination policies (30). Based on current 
databases there is no documented combined synthesis for both qualitative and quantitative 
data in answering the ‘why’ and ‘what’ reasons for decline. Furthermore previous reviews did 
not consider girl’s age range of 10-14. The parental role in HPV acceptance or refusal needs 
to be reviewed in finding their experiences to refusal which may assist in future decision 
making by public health implementers (31) 
2.4 RESEARCH QUESTION 
Why are parents making a decision to delay or refuse their daughters aged 9-17 to be 
vaccinated against HPV within high-income OECD countries? 
2.5 STUDY OBJECTIVES. 
This study review had two objectives which were: 
i. To determine and identify themes, factors and barriers explaining why parents decide 
to delay or refuse to accept HPV vaccination for their daughters aged 9-17 through a 
systematic review of quantitative and qualitative primary studies. 
ii. Based on reported media reports in both USA and Japan, this research had an 
objective to determine the role played by social media and religion in parental decline 








METHODS AND DESIGN 
3.0 RESEARCH PROTOCOL. 
The protocol for this systematic review study was registered and accepted by PROSPERO 
number CRD42016033820 (32). The systematic review method by Joanna Briggs Institute 
with research quick reference guide was used (33, 34). The next step was the identification of 
all qualitative and quantitative required articles on the topic of interest with needed data for 
this research. The articles answering research question were classified based on search 
strategies and inclusion-exclusion criteria. 
3.1 LITERATURE SEARCH STRATEGIES. 
The initial search from MEDLINE using Papillomavirus Vaccines"[Mesh] AND 
("Parents"[Mesh]) AND ( "Refusal to Participate"[Mesh] OR "Refusal to Treat"[Mesh] OR 
"Treatment Refusal"[Mesh] OR "Withholding Treatment"[Mesh] OR "Medication 
Adherence"[Mesh] OR "Proxy"[Mesh] OR "Patient Participation"[Mesh] OR "Patient 
Compliance"[Mesh] OR "Denial (Psychology)"[Mesh] yielded few hits. 
The researcher then conducted a broad, in-depth search that was comprehensive to capture all 
detailed and relevant articles for this review. The population, place, people, problem and 
participants criterion,was set. The intervention method used was HPV vaccination acceptance 
or rejection with research interest on those who have rejected. The outcomes of interest were 
determined before commencing the search as parents who have not vaccinated their 
girls/daughters against HPV by either delaying or refusing to accept HPV vaccination. It was 
noted that some quantitative research articles had a comparison of HPV and other childhood 
vaccines uptake. Anti-vaccination campaign sites and blogs were searched to find if there was 
any published work on their activism as part of pre-research data gathering.  These databases 
that were applied included: PUBMED-MEDLINE, SCOPUS, CINAHL, Global health 
library,UiT (University of Tromsø) Library, Web of Science, HighWire, Google Scholar, 
science.gov, Grey Literature Library and individual country HPV vaccination sites. 
Additional university sites were searched for theses that were not yet published as part of grey 
literature. The reference sites abstracts were saved using EndNote ×7.4 software. Some 
abstracts were copied and pasted in a particular file of abstracts in word format. The terms 
used were; 
Parents  OR  guardians  OR  girls  OR  daughters  AND HPV  vaccination  OR  human 
papillomavirusvaccination  OR  HPV  immunization  OR  cervical cancer vaccination  AND 
HPVvaccination barriers  OR  HPV  vaccination challenges  OR  human papillomavirus 
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vaccination refusal  OR  HPV  vaccination delay OR HPV vaccination hesitation. Mesh terms 
were used during the search and limits were applied for years with all languages allowed. 
Hand searching was done on reference lists to identify papers that could not be found through 
the internet search. 
3.2 INCLUSION AND EXCLUSION CRITERIA. 
Articles with data from non-vaccinated girls aged from 9 to 17 were included. Articles with 
parental response to girls aged 18 were included based on the age of consent which is done by 
the parent or if the decision not to vaccinate was done before age 18. Those above 18 years 
were excluded as well as all boys. Only primary data articles that were researched within 
OECD countries which numbers to 34 were considered (35). Data from nations with HPV 
vaccination policy and program were considered while countries in OECD without HPV 
vaccination program were not included. Countries with the recently introduced national 
program were excluded from the review. The excluded countries were Turkey, Hungary, 
Poland, Estonia and Slovakia (36-40) having proposed programs after 2014 or did not have a 
vaccination programme. Publications from January 2009 to January 2016 were included in the 
search. Only articles with data gathered involving parents or guardians or girls in allocated 
age were included. Research articles with data from health practitioners and other HPV 
vaccination groups were included in this review. Review articles and randomized control 
studies were excluded.  The language of publication was not limited and it included articles in 
English, French, Italian, Spanish, Korean and any other language spoken in the OECD 
countries. The researchers included Grey articles and unpublished but valuable sources based 
on content and relevance to the topic of review. Both qualitative and quantitative research 
articles were included. Articles with girls or daughters contribution without parental 
involvement were excluded unless parental consent was given before data collection. Primary 
articles with responses from Human Immuno-deficiency Virus (HIV) infected girls were 
excluded. Articles with girls as study subjects were not considered as the researcher’s interest 
were on parental responses. Articles which had both parents and daughters views were 
included with only parental responses considered. This review population of interest was 
parents who have declined HPV vaccination. To enable extraction based on the method 
chosen, only qualitative studies with stated quantifiable numbers of interviewees were 
included. Quantitative primary sources with reported findings as odds ratios (with no actual 
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3.3 SYSTEMATIC REVIEW STUDY SELECTION. 
The researcher assessed the primary articles abstracts from the exhaustive literature search 
independently and made a decision based on the headline, topic and the abstract content. 
Articles that were fit to be included in the synthesis were selected for further checks. A few 
database sites were searched independently by an externally requested researcher (Femi) for 
credibility and reduction of bias which yielded close results regarding article numbers. This 
review had the external reviewer and the researcher disagreeing on the inclusion of some 
articles, a third tie-breaker (Stanislav) were contacted for articles with disagreements and a 
consensus was reached. The two lists made with the articles were compared, and a consensus 
was attained on those to be included based on set criteria. The researcher did further hand 
searching from reference lists and other systematic reviews related to the topic of interest to 
increase the number of primary studies. 
3.4 QUALITY ASSESMENT OF PRIMARY DATA. 
Cohort and qualitative research articles were appraised using the Critical Appraisal Skills 
Programme tool (CASP) for (42). The Assessment of methodological selection, response and 
observation of methodological bias was done and the usefulness of reports determined (43). 
The researcher utilised Stanford University critical appraisal tool for cross-sectional studies in 
cross sectional studies (44). An additional tool was added for assessment of selection, 
performance, attrition, detection and reporting biases for quantitative studies (45). The 
researcher and external reviewer agreed on all 32 articles appraisal list using the fore 
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mentioned tools. All included primary studies were based on critical appraisal results. One 
thesis was included in this review despite low quality and bias, the researcher consulted the 
independent reviewer and a consensus was reached (46). One article was removed despite 
qualifying during appraisal based on consent by the subjects who were considered minors. 
Although our target age was girls below 17 years, one article had aggregated age of 16-18  
which still required parental consent (47). The researcher contacted primary authors by emails 
and phones to obtain clarifications and additional information on primary data of interest 
before decisions were made. 
3.5 METHOD FOR DATA SYNTHESIS. 
Qualitative Meta-summary process. 
The data synthesis was done according to the method developed by Sandelowski (Handbook 
for Synthesizing Qualitative Research page 151-196). The method included several 
techniques in data synthesis that consisted of extraction, separation of findings, editing of 
findings, grouping of similar findings, abstraction and Size effect calculation (41, 48). 
Extraction of findings 
The process involved classifications, setting of criteria and identifications of themes, 
observations, responses and generated data from questionnaires. The target population for 
extraction were set and only responses from parents in quantitative articles were considered. 
The subject’s responses by parents with non-vaccinated daughters were considered for this 
synthesis. Non-specific responses grouped as ‘other’ ‘no reasons’ and ‘non-stated reasons’ 
were excluded while ‘most’ ‘almost’ and ‘some’ were translated to percentages as 
recommended by primary authors consideration. Responses with less than 1% and having 
sample size of less than twenty were not extracted. Articles with results reported as standard 
deviations were calculated using total numbers to give them a quantifiable estimated figure 
for this review (49-52). The researcher considered themes from qualitative research while all 
primary authors were excluded (48). 
Separating of findings. 
The researcher separated the discussions, quotations, stories, and cases that had been used in 
generating the final results. Attention was paid to all comparison from previous studies, 
analytical procedures and coding’s from the primary sources with intention of clearly 
separating them. each findings were treated as a unit and linked to the sources with 
participants thoughts, feelings, responses, opinions and behaviours considered collectively for 




Editing the findings 
The researcher maintained closeness to primary author’s findings while maintaining the 
original meanings and findings while avoiding any distortions. All findings had responses 
indicated for additional purposes as the numerical strength was an important part of 
extraction.  
Grouping of similar findings. 
The findings were judged based on the content and re-reading. Those with similarities from 
each primary research were grouped together to form several groups (48). Their size effects 
were noted through percentages where all responses were added to a total number 
representing 100%. The finding result total number of responses from the parents were added 
together and a percentage calculated using the overall total responses. 
Abstracting of findings. 
 The extracted, separated, edited and grouped findings underwent further abstraction process.  
This involved further reduction of many statements of extracted, edited and grouped findings 
into more parsimonious groups (48). Abstraction involved back and forth editing between 
statements which were topically similar from extracted findings. This led to development of 
statements that led to final set that captured the content of all findings while preserving the 
context (48). Files were created to suit new category of groups which depended on parental 
factors, girl child related factors, health provider, pharmaceutical companies, government and 
media factors (41, 48). 
Size effect calculation. 
This involved calculating manifest frequency and intensity effect with magnitude of size 
noted. All the similar grouped findings had percentages which were added after abstraction. 
The total effect was noted with all responses from abstracted data totalling to 100%.  
Justification of Qualitative Meta-summary method 
Research synthesis methods are variant as noted by several researchers. According to several 
authors (30, 41, 53) both qualitative and quantitative primary articles have been integrated 
using mixed methods. This has been done independently with qualitative and quantitative 
findings assembled separately. The major challenge previously encountered by researchers 
has been merging together of qualitative and quantitative findings to give systematic reviews 
the statistical strength while preserving the content. This synthesis had primary data either 
quantitative or qualitative based on interviews or questionnaires addressing the ‘what’ and 
‘why’ parents took the decision not to accept HPV vaccination. The presumed differences 
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between quantitative and qualitative data could only be bridged using Qualitative Meta-
summary method (41, 48). 
Previous studies in the USA utilised meta-analysis and thematic synthesis separately with 
different reviews (30, 54). The reasons based on responses from questionnaires in quantitative 
primary data had variant findings which addressed ‘What’ part. The second review addressed 
‘Why’ components using qualitative data. There was a reported previous major challenge of 
how to integrate and combine the two methods while answering this research question. This 
review addressed this by extraction, separation of findings, editing of findings, grouping of 
similar findings, abstraction and Size effect calculation (41). The Qualitative Meta-summary 
method as applied by the researcher could address the could address the ‘why’ and ‘what’ of 
the research question (55). 
3.6 GENERAL EXTRACTION OF QUALITATIVE AND QUANTITATIVE DATA. 
Although the researcher’s intention was to combine the articles using Qualitative 
Metasummary synthesis, comparison between qualitative and quantitative articles could give 
further details. Before synthesis was done, different primary articles were extracted to give a 
general view of the included data. The qualitative data for this research were extracted using 
QARI tool which was captured the details of interest according to this systematic review (34). 
Quantitative data was entered into Excel spread sheet with created titles including authors, 
year of research and publication, the location of the study and type of settings. The QARI 
extraction tool included methods, settings, geographical context and participants. This 
similarities and differences were noted and highlighted in discussion of this review. 
Quantitative primary research extraction tool was developed in Microsoft Excel to suit this 
review. The details were finally combined and included in general extraction table. The 
details included: study authors, place/subjects of interest location, participants and population 
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Additional records identified 
through other sources (n = 3) 
Records before duplicates are removed  
(n = 82) 
Records screened n = 28 (Researcher 
and independent reviewer) 
Records excluded with reasons (n = 
49)9= repetitions 
12=not population of interest. 
14= did not meet inclusion criteria. 
2 = reports and reviews. 
13= mixed population, no decline 
reasons, undecided decision, only 
abstracts retrieved, non-parental 
participation involvement. 




(n = 28) Full-text articles assessed for 
eligibility (Researcher and reviewer) 
 
Full-text articles and abstracts 
excluded, with reasons n =5 
1 qualitative low score 
3 quantitative studies with no 
outcome explanations. 
1 low score involving girls under 
18 with no parental consent 
 
Qualitative Studies included in synthesis  
n = 10 (including 2 with both methods) 
 
Quantitative Studies included in synthesis 
narrative analysis (n = 13) 
1 cohort, 12 cross sectional studies. 
 
INITIAL SELECTION OF ALL ARTICLES. 
n = 1279 (researcher) 
IDENTIFICATION AND SEARCH OF ALL DATABASES’ = 
3973 articles identified (researcher) 
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CHAPTER 4  
4.0 STUDY RESULTS - DATA CHARACTERISTICS. 
Several data bases were searched, and all the results were combined yielding 3173 articles 
related to HPV vaccination. Further refining by the researcher based on inclusion-exclusion 
criteria was done, and 1279 articles identified. All the abstracts for 1279 articles underwent 
quick preview with filters applied for the year of research and publication, human subjects, 
abstracts availability with a focus on identifying articles of interest. A total of seventy nine 
articles had been identified with three added from hand searching. Twenty eight articles were 
selected for appraisal by the systematic synthesis reviewer and external reviewer by 
consensus. They both appraised the articles independently, and ten qualitative and thirteen 
quantitative were agreed for final inclusion (figure 1).There were twelve articles categorised 
as cross-sectional studies and one cohort study. There were ten qualitative studies which 
included two with both quantitative and qualitative methodologies with qualitative part 
meeting the set criteria for this study. 
4.1 RESEARCH RESULT- PARTICIPANT CHARACTERISTICS. 
The majority of studies (n=14) representing 60% of the data were undertaken in the USA. The 
remaining (n=9) were one each from South Korea, Canada, United Kingdom, New Zealand, 
France, Sweden, Italy, Japan and Netherlands (Table 1). The population involved was parents, 
guardians or caretakers of daughters or female children aged between 9-18 years. The parental 
reported mean age ranged from 41-45.1 years across all the study groups. Most studies and 
data collection was undertaken from 2007-2013 with the majority of studies done from 2008 
until 2013. The intervention involved offers to vaccinate girls aged 9-18 by General 
practitioner (GP), paediatrics units, children’s hospitals,  school-based nurse, Gynaecologist 
and other vaccination centres in different countries. Health facilities including Outpatient, 
paediatrics units and children’s hospital formed majority of participants location (n=9). Other 
areas included nationwide based surveys (n=5), school-based programs (n=4) and county, 
state or regional based study locations (n=5). The majority of primary studies included in this 
review (n=13) collected their data using questionnaires, interviews (n=8) and both 
methodologies (n=2). One study had a comparison of  HPV vaccination to Pap smear check-
up which is only applicable to older women and not under 18 years girls (57).  The outcome 
of interest included parental reluctance to accept, refusal, and delay or deferral of HPV 
vaccination for their daughters (Table 1). 
Most of the primary data collection had been done in English (n=13), English and Spanish 
combination (n=3) English Spanish and Haitian Creole combination (n=1). Those originally 
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collected in Italian, Korean, Japanese, French, Dutch-Somali combination and Swedish had 
one initial article each (n=6).  All articles were published or translated to English even though 
the first language was non-English.  A total of 38577 parents participated in both quantitative 
and qualitative primary research. Bias assessment was done using CASP and stanford 
University tool for bias assesment with  majority of the dat having low to medium bias 
(n=22) . One article was included based on consensus despite having a high bias. The 
researcher and external reviewer evaluated the article independently, and there was no 
agreement until a third independent tie-breaker had to conclude. The article was included 
based on the understanding that low sample size might have caused it. Different data articles 
had differing conclusions by the authors ranging from parental responsibility with the public 


























4.2 META SUMMARY RESULTS-EXTRACTED OUTCOMES. 
A total of twenty three articles from the primary research were considered consisting of 
15458 parents as participants. The 23 primary data had a total of 246 reasons given by 15458 
parents on why they delayed, refused, rejected or both to HPV vaccination to their daughters 
aged 9-17 years. These reasons were either similar or different from each primary article 
(table 2). These were based on interviews and questionnaires obtained from the results, with 
discussions and primary researcher’s views excluded. The qualitative articles had 62 reasons, 
and quantitative contributed to 184 total reasons from parents. The article with the highest 
number of reasons given had 23 while the lowest had two reasons (51, 58). The 246 reasons 
had 31740 responses from 15458 parents indicating an average of 129 responses for every 
reason given by parents for parents giving more than one response for different reasons (table 
2).  
4.3 SEPARATED AND EDITED FINDINGS. 
Among the 246 reasons given, several of them were similar with different authors enabling 
grouping together. Similar reasons from both qualitative of quantitative studies were 
identified, scrutinized and compared by researcher before pooling together. The merged 
similar reasons produced 20 grouped finding (Table 2 Categories column).  
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used  HPV 
Vaccination 
Reasons  for decline of HPV vaccination grouping 









et al.  
53 19 Vaccine safety (not enough data on safety, vaccines 
are linked to autism, many vaccines are declared safe 
but later become unsafe)  
1 n=8 
low perceived risk of infection(no family cancer 
history, cervical cancer is not deadly, daughter taught 
the right thing to do, HPV not contagious) 
9 n=7 
Age-related (too young, wish to wait until older age, it 
can harm an adolescent.) 
2 n=7 
Knowledge related (need more personal information, 
medical establishment need to know more on HPV 
vaccine) 
12 n=6 
Financial issue/cost (lack of insurance coverage). 10 n=3 
Physician’s recommendations to wait on the vaccine. 13 n=2 
Deep beliefs about vaccines (problematic to get several 




Control over health-related decision (daughter will 
make her decision, daughter did not want the vaccine) 
4 n=2 




886 780 Need more information about the vaccine. 12 n=169 
Daughter too young  2 n=128 
Never heard of the vaccine or not aware  daughter 
could get it  
6 n=118 
Haven’t been to the doctor gotten around to it yet 13 n=99 
Daughter isn’t having sex yet. 3 n=98 
Doctor did not recommend vaccine or  recommended 
against it  
13 n=57 
The vaccine is too new. 6 n=52 
The vaccine is not necessary or daughter not at risk. 8 n=35 
The vaccine is unsafe. 1 n=30 
Vaccine not available yet. 19 n=27 
Still deciding. 6 n=13 
Vaccine costs too much. 10 n=12 
Health insurance doesn’t cover the vaccine. 10 n=12 
Daughter has a fear of shots. 15 n=6 
The parent did not ask the provider about the vaccine. 13 n=6 




73 38 Parental attitudes (needs more information). 12 n=22 
Missed opportunity MD did not offer the vaccine. 13 n=8 
Parents have concerns about safety. 1 n=7 
Lack of access Not had time to go to the doctor. 19 n=6 
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Other:distrust of “government “biased approach, and 
daughter does not need it. 
18 n=6 
Vaccine too expensive/not covered by insurance. 10 n=3 
The parent does not know where to get it. 19 N=3 
Parents worried that vaccine will encourage daughter 
to have sex 
14 n=3 
Religious beliefs oppose it. 17 n=3 




Gupta  et al 
2786 560 Vaccine safety concern/side effects. 1 n=156 
Vaccination not needed or not necessary. 8 n=99 
Daughter not sexually active. 3 n=96 
Lack of knowledge. 12 n=89 
Did not receive provider recommendation. 13 n=54 
Daughter not appropriate age. 2 n=38 
Family/parent decision. 17 n=20 
Need more information/new vaccine. 12 n =19 
Costs. 10 n=15 
The daughter should make a decision. 4 n=11 
Don’t believe in vaccinations. 7 n=7 
Handicapped/special needs/illness. 16 n=5 
Not a school requirement. 8 n=4 
Daughter fearful. 15 n=4 
No doctor or doctor’s visit not scheduled. 13 n=2 
Religion/orthodox. 17 n=2 





667 657 The HPV vaccine is not popular. 6 n=557 
Not many people I know had been vaccinated. 6 n=556 
Nobody had recommended. 13 n=543 
High cost. 10 n=540 
Unfamiliar. 6 n=532 
Don’t know where to go. 19 n=505 
Doubt on effectiveness. 11 n=449 
Fear of injection. 15 n=427 
Mistrust. 7 n=420 
Long distance. 19 n=405 
Low risk. 9 n=403 




2025 697 Safety of the vaccine. 1 n=209 
Prefer to wait until daughter is older. 2 n=110 
No enough information to make an informed decision. 12 n=87 
The vaccine is too new. 6 n=50 
Daughter not at risk of cervical cancer. 9 n=37 
I do not believe in vaccines, HPV no different. 7 n=18 
My physician advised me not to have Daughter receive 13 n=17 
Daughter is too young. 2 n=14 
More research needed. 11 n=13 
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Daughter is not sexually active. 3 n=13 
Vaccine is a ploy by pharmaceutical company. 18 n=12 
Consent will encourage sexual activity. 14 n=11 
Will educate daughter on abstinence & safe sex. 5 n=10 




2205 1105 Does not need vaccine. 8 n=238 
Does not know enough about vaccine. 12 n=196 
 Not sexually active. 3 n=162 
Worried about safety of vaccine. 1 n=160 
Too young for vaccine. 2 n=109 
Doctor did not recommend it. 13 n=61 




20 11 Children not at risk (not the right time, Too young 








20 10 Low risk, not sexually active. 3 n=10 
Cultural and religious norms protection against sex. 17 n=10 
Safety concerns(new, untested,   from nowhere) 1 n=9 
No herd immunity(sexually transmitted) no need 8 n=1 
Too young (should wait for suitable age) 2 n=8 
Media reports on the vaccine. 20 n=2 




501 256 Concern for vaccine side effect. 1 n=90 
Concern for danger to daughter. 1 n=90 
Provider non-recommendation. 13 n=86 
Doubt of vaccine efficacy. 11 n=33 
Long lapse in doctor’s visit. 19 n=29 
Lack of insurance or finance. 10 n=28 
Concern for increased ease for daughter to have sex 14 n=19 
Tabassum 
H. Laz, et 
al. 
2171 910 Does not need the vaccine. 8 n=233 
Worried about vaccine safety. 1 n=176 
Do not know enough about the vaccine. 12 n=151 
Not sexually active. 3 n=102 
Too young for the vaccine. 2 n=59 
Doctor did not recommend. 13 n=50 
Too expensive. 10 n=11 
Alice Ma 
et al. 
86 35 This vaccine is too new, and more  research  needed 6 n=26 
I am concerned about the safety of this vaccine.  1 n=21 
My daughter is too young. 2 n=15 
My daughter is not sexually active. 3 n=14 
I will educate my daughter about abstinence  and safe 
sex instead  
5 n=9 
My daughter is not at  risk of cervical cancer 9 n=8 
I don’t think I received enough information to make an 
Informed choice.  
12 n=7 
I felt rushed/pressured to make a decision. 18 n=6 
I don’t trust pharmaceutical companies. 18 n=5 
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The information I read onthe internet about it. 20 n=5 
Medical reasons (e.g. prior allergic reaction to vaccine)  16 n=2 
I don’t want to expose my daughter to too many 
needles   
15 n=2 
I don’t trust the public healthcare system. 18 n=2 
It might encourage dangerous and Inappropriate sexual 
behaviour   
14 n=2 




210 80 More information New drug, Low experience feared 
side effects. 
1 n=41 
Wait for physician’s decision and opinion. 13 n=22 
Daughters will make their decision. 4 n=15 
Too early to discuss the sexual matters, this will 
encourage early sexual activity.  
14 n=5 
Preference to pap smear than HPV. 5 n=4 




Katz et al. 
1951 587 Vaccination not needed or not necessary. 8 n=116 
Daughter not sexually active. 3 n=106 
Lack of knowledge. 12 n=99 
Vaccine safety concern/side effects. 1 n=73 
Did not receive provider recommendation. 13 n=61 
Daughter not appropriate age. 2 n=45 
Need more information/new vaccine. 12 n=30 
Costs. 10 n=21 
Family/parents’ decision. 17 n=19 
Child fearful. 15 n=12 
Handicapped/special needs/illness. 16 n=9 
No doctor or doctor’s visit not scheduled. 13 n=6 
The child should make a decision. 4 n=6 
Don’t believe in vaccinations. 7 n=5 
Not a school requirement. 8 n=4 
No obstetrician/gynaecologist. 13 n=3 
Increased sexual activity concern. 14 n=2 
Effectiveness concern. 11 n=2 
Daughter already sexually active. 3 n=1 




25 25 Inadequate information given. 12 n=16 
It will encourage sex easily. 14 n=14 
Too young. 2 n=13 
New vaccine scepticism. 6 n=13 
She will decide on her own. 4 n=12 
Other preventive methods should be offered instead. 5 n=11 
She is scared of needles. 15 n=10 
Other existing conditions (diabetes, asthma). 16 n=8 
Advised by professionals not to allow. 13 n=7 
The school nurse was not supportive, knew less. 12 n=6 
Religious and faith do not allow. 17 n=4 
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Vaccine not needed-don’t need to vaccinate everything 8 n=4 
No trust in government, too pushing. 18 n=4 
Previous vaccination mistakes (H1N1) memories. 18 n=3 
Individual freedom, more thinking and reflection 19 n=2 
Jessica L. 
Vercruysse 
62 25 Side effects. 1 n=9 
Peer and media influence. 20 n=9 
Lack of knowledge on HPV vaccine. 12 n=15 
The newness of the vaccine. 6 n=10 
Religious beliefs (vaccine un-necessary). 17 n=8 
Needle phobia and Number of doses. 15 n=12 




4103 1377 Concerns about lasting health problems. 1 n=847 
Wonder about the effectiveness of the vaccine. 11 n=739 
The teen is not sexually active. 3 n=727 
The belief that the vaccine is not needed. 8 n=681 
Heard, read bad things about the vaccine in the news 
TV, the radio, in the newspaper, or on the Internet. 
20 n=567 
Lack knowledge about the vaccine. 12 n=480 
Feel that there are too many shots. 15 n=368 
The vaccine was not recommended by. Health care 
provider. 
13 n=279 
Have concerns about short-term problems, like fever 
or discomfort  
1 n=262 
Getting the vaccine was not convenient. 8 n=142 
The teenager was ill at the time. 16 n=130 
Have concerns about cost. 10 n=96 
Missed or couldn’t get an appointment. 13 n=47 
Unable to find a health care provider who had the 




R. Cates et 
al. 
617 419 Less information more needed. 12 n=87 
Too young for vaccination. 2 n=86 
Safety and side effects. 1 n=56 
The drug is too new. 6 n=53 
No healthcare provider recommendation. 13 n=53 
Daughter not sexually active. 3 n=21 




1738 1331 Fear of adverse events. 1 n=1064 
No confidence in a new vaccine. 7 n=1012 
Discordant information on HPV vaccination. 12 n=865 
Scarce information on HPV vaccination. 12 n=719 
Regular pap-test can prevent cervical cancer. 5 n=665 
Our daughter is young and not sexually active. 2 n=599 
HPV vaccination not useful. 8 n=545 
HPV vaccination not compulsory. 8 n=505 
No confidence in vaccinations. 7 n=452 
Other health care workers’ advice Against vaccination. 13 n=373 




Familiars/friends' advice against HPV vaccination. 13 n=319 
Scarce promotion of HPV vaccination. 12 n=292 
HPV vaccination promotes sexual risk behaviours. 14 n=213 
Fear of injection. 15 n=186 
HPV infection is not severe. 9 n=186 
Contraindications to vaccination. 16 n=106 
Alternative medical approach, excluding vaccinations 5 n=106 
We were not able to respect the date. 19 n=53 
We did not know that HPV vaccine was free-of-charge 12 n=53 
Getting a date for vaccination is difficult. 19 n=26 
Vaccination service is difficult to reach. 19 n=13 




124 53 The vaccine was never offered. 13 n=23 
Luck of information. 12 n=11 
Too young for the vaccine. 2 n=7 
Safety concerns. 1 n=6 
Not necessary, she is abstaining. 3 n=3 
Vaccination could promote unsafe sex. 14 n=2 




20 4 Distrust in HPV vaccine safety and side effects. 1 n=4 
Not sexually active, no boyfriend. 3 n=3 
Respect adolescent’s opinion. 4 n=2 
Embarrassed explaining sexual intercourse details. 19 n=2 
The cost, it’s expensive. 10 n=2 
Bad publicity regarding HPV vaccination. 20 n=2 
Jihan Salad 
et el. 
6 2 Unknown and negative side effects. 1 n=2 
Objects of research. 11 n=2 
The government is encouraging sex. 14 n=2 
Too young for HPV vaccination. 2 n=2 











































Vaccination not needed or not necessary. 8 n=1189 
Daughter not sexually active. 3 n=1171 
Lack of knowledge. 12 n=1089 
Did not receive provider recommendation. 13 n=742 
Safety concerns/adverse effects. 1 n=478 
Daughter not appropriate age. 2 n=473 
More information/new vaccine. 12 n=321 
Family/parents’ decision. 17 n=238 
Costs. 10 n=162 
Child should make decision. 4 n=92 
Handicapped/special needs/illness. 16 n=68 
Child fearful. 15 n=59 
No doctor or doctor’s visit not scheduled. 13 n=48 
23 38582 15458 246 20 31740 
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4.4 GROUPED SIMILAR FINDINGS. 
The findings in 20 groups were calculated from the total responses to obtain the effect of 
size. Less information and knowledge contributed the highest percentage of 15.22% of the 
total responses with 25/246 reasons representing 10.2% of overall findings. Lack of trust in 
government and pharmaceuticals represented the lowest percentage of responses with 0.12%.  
Advice from a general practitioner and other healthcare providers had the highest number of 
reasons given (29/246) from 19 articles. Safety and side effects were the greatest most reason 
given by authors represented 91% (21/23) of primary data with nine qualitative articles and 
12 quantitative (Table 3).  
Table 3: grouped similar findings with size effect (31740 responses representing the total) 
                                                  Table 3. 













By %  
1 Safety and side 
effects 
Unsafe, untested, 
distrust in vaccine 
due to side effects, 
unknown adverse 
effects, the concern 
of lasting health 
problem, not enough 
data, fear for adverse 
events. 
Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Nava Yeganeh et al,.Paul L. Reiter, Kunal 
Gupta et al and Gina Ogilvie et al. Charlene A. 
Wong et al., Cayce C. Hughes et al., Daniel 
Gordon et al, and  Laura M. Kester et al. 
Tabassum H. Laz, et al. Alice Ma et al. ,Julie 
Haesebaert et al. Paul L. Reiter, Mira L. Katz et 
al.andJessica L. Vercruysse. Christina Dorell et 
al. Paul L. Reiter, Joan R. Cates et al. Cristina 
Giambi et al. Rebecca B. Perkins, et al. 
RieWakimizu et al. Jihan Salad et al. Christina 





















Nine quantitative and twelve qualitative articles. 
2 Daughter/ girl/child 
age 
Too young, not 
appropriate age, wait 
until an older age, 
prefer to wait, not 
the right time. 
Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Paul L. Reiter, Kunal Gupta  et al., Gina 
Ogilvie et al., Charlene A. Wong et al., Cayce C. 
Hughes et al., Daniel Gordon et al., Tabassum H. 
Laz, et al. Alice Ma et al., Paul L. Reiter, Mira L. 
Katz et al., Maria Grandahl et al., Paul L. Reiter 
Joan R. Cates et al., Cristina Giambi et al., 
Rebecca B. Perkins, et al., Jihan Salad et al., 
















 Nine quantitative, seven qualitative 
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3 Daughter  sexually 
active/non-active 
Not yet having sex, 
already having a 
boyfriend, no 
boyfriend yet, she is 
abstaining,  
Sami L. Gottlieb et al., Paul L. Reiter, Kunal 
Gupta et al., Gina Ogilvie et al., Charlene A. 
Wong et al., Daniel Gordon et al., Tabassum H. 
Laz, et al., Alice Ma et al., Paul L. Reiter, Mira 
L. Katz et al., Christina Dorell et al., Paul L. 
Reiter Joan R. Cates et al., Rebecca B. Perkins, 
et al., RieWakimizu et al., Christina G. Dorell, 













Four qualitative and nine quantitative 
4 Daughter decide 
She will make her 
decision; she will 
decide on her own; I 
respect adolescent 
opinion,  
Amanda F. Dempsey et al., Paul L. Reiter, Kunal 
Gupta et al., Julie Haesebaert et al., Paul L. 
Reiter, Mira L. Katz et al., Maria Grandahl et al., 
RieWakimizu et al., Christina G. Dorell, Tammy 













Four qualitative, three quantitative 
5 Other methods 
She is abstaining, 
other methods will 
do, regular pap 





Gina Ogilvie et al., Alice Ma et al., Julie 
Haesebaert et al., Maria Grandahl et al., Cristina 



















Two qualitative and three quantitative 
6 Doubts on HPV 
vaccine 
The new vaccine, 
never heard of it, not 
popular, not so many 
are vaccinated, still 
deciding. 
Sami L. Gottlieb et al., Hee Sun Kang, Linda 
Moneyham., Gina Ogilvie et al., Alice Ma et al., 
Maria Grandahl et al., Jessica L. Vercruysse., 










Three qualitative, four quantitative 
7 No trust in drug 
Don’t believe in the 
drug/ vaccination, no 
confidence, mistrust 
in drug 
Paul L. Reiter, Kunal Gupta  et al., Hee Sun 
Kang, Linda Moneyham., Gina Ogilvie et al., 
Paul L. Reiter, Mira L. Katz et al., Cristina 













Five quantitative articles. 





Sami L. Gottlieb et al., Paul L. Reiter, Kunal 
Gupta  et al., Charlene A. Wong et al., Daniel 
Gordon et al,. Tabassum H. Laz, et al., Paul L. 
Reiter, Mira L. Katz et al., Maria Grandahl et al., 
Christina Dorell et al,. Cristina Giambi et al., 

















three qualitative and seven quantitative 
9 Low risk to cervical 
cancer   
Low perceived risk, 
infection not 
common,  
Amanda F. Dempsey et al., Hee Sun Kang, 
Linda Moneyham., Gina Ogilvie et al., Alice Ma 













one qualitative and four quantitative 
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10 Cost related. 




Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Nava Yeganeh et al., Paul L. Reiter, Kunal 
Gupta  et al., Hee Sun Kang, Linda Moneyham., 
Charlene A. Wong et al., Laura M. Kester et al., 
Tabassum H. Laz, et al., Paul L. Reiter, Mira L. 
Katz et al. Christina Dorell et al., Rie Wakimizu 
et al., Christina G. Dorell, Tammy A. 













Three qualitative and ten quantitative. 
11 Doubt on 
effectiveness 
Objects of research, 
more research 
needed 
Paul L. Reiter, Kunal Gupta et al., Hee Sun 
Kang, Linda Moneyham., Gina Ogilvie et al., 
Laura M. Kester et al., Paul L. Reiter, Mira L. 














one qualitative and six quantitative 









Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Nava Yeganeh et al., Paul L. Reiter, Kunal 
Gupta  et al., Gina Ogilvie et al. Charlene A. 
Wong et al., Daniel Gordon et al., Tabassum H. 
Laz, et al., Alice Ma et al., Paul L. Reiter, Mira 
L. Katz et al., Maria Grandahl et al., Jessica L. 
Vercruysse., Christina Dorell et al. Paul L. Reiter 
Joan R. Cates et al., Cristina Giambi et al., 
Rebecca B. Perkins, et al. Jihan Salad et al., 




















Seven qualitative and eleven quantitative 
13 Advised against, no 
visit or no 
recommendation. 








friends and health 
facility. 
Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Nava Yeganeh et al., Paul L. Reiter, Kunal 
Gupta  et al., Hee Sun Kang, Linda Moneyham., 
Gina Ogilvie et al., Charlene A. Wong et al., 
Laura M. Kester et al., Tabassum H. Laz, et al., 
Alice Ma et al., Julie Haesebaert et al., Paul L. 
Reiter, Mira L. Katz et al., Maria Grandahl et al., 
Jessica L. Vercruysse., Christina Dorell et al., 
Cristina Giambi et al., Rebecca B. Perkins, et al., 



















Six qualitative and thirteen quantitative 





behaviour & unsafe 
sex. 
Sami L. Gottlieb et al., Nava Yeganeh et al., 
Gina Ogilvie et al., Laura M. Kester et al., Alice 
Ma et al., Julie Haesebaert et al., Paul L. Reiter, 
Mira L. Katz et al., Maria Grandahl et al., Paul 
L. Reiter Joan R. Cates et al., Cristina Giambi et 
















Five qualitative and seven quantitative 
26 
 
15 Fear of Injections. 
Too many injections 
or needles, needle 
phobia, scaring. 
Amanda F. Dempsey et al., Sami L. Gottlieb et 
al., Paul L. Reiter, Kunal Gupta  et al., Hee Sun 
Kang, Linda Moneyham., Gina Ogilvie et al., 
Alice Ma et al., Paul L. Reiter, Mira L. Katz et 
al., Maria Grandahl et al., Jessica L. Vercruysse., 
Christina Dorell et al., Cristina Giambi et al., 













Four qualitative eight quantitative 





medical reasons and 
sickness. 
Paul L. Reiter, Kunal Gupta  et al., Alice Ma et 
al., Paul L. Reiter, Mira L. Katz et al., Maria 
Grandahl et al., Christina Dorell et al., Cristina 
Giambi et al., Christina G. Dorell, Tammy A. 

















one qualitative and six quantitative 
17 Religion and family 





cultural and religious 
values. 
Amanda F. Dempsey et al., Nava Yeganeh et al., 
Paul L. Reiter, Kunal Gupta  et al., Daniel 
Gordon et al., Paul L. Reiter, Mira L. Katz et al., 
Maria Grandahl et al., Jessica L. Vercruysse., 
Cristina Giambi et al., Christina G. Dorell, 

















four qualitative and five quantitative 








Nava Yeganeh et al., Gina Ogilvie et al., Alice 










one qualitative three quantitative 
19 Difficulty in 
obtaining services. 
Vaccine not 
available, no access, 
any time, no 
provider, could not 
make it on time, 
individual freedom 
threat, long queue, 
distance. 
Sami L. Gottlieb et al., Nava Yeganeh et al., Hee 
Sun Kang, Linda Moneyham., Laura M. Kester 
et al., Maria Grandahl et al., Christina Dorell et 



















3 qualitative and 4 quantitative 
20 Media and internet 
influence 
Information read 
online, peer and 
media influence, bad 
publicity, media 
reports. 
Daniel Gordon et al., Alice Ma et al., Jessica L. 
Vercruysse., Christina Dorell et al., Rie 










4 qualitative and 1 quantitative 
   23 246 31740 
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4.5 ABSTRACTED RESULTS WITH CALCULATED SIZE EFFECT 
This research identified 20 different reasons directed towards vaccine, parents, girl child, 
general provider and pharmaceutical. The twenty major findings were further abstracted to 
form seven groups with the size effect noted based on collective responses. After extraction 
separtion, editing, grouping of similar responses and abstraction of findings, several grouped 
results were carefuly formulated. The seven  abstracted results included  (a) vaccine related 
(b) parental concerns and perceptions (c) girl child factors (d) general factors (e) health 
provider factors (f) pharmaceutical and government-related factors and (g) social media and 
religious concerns. Primary data had safety and side effects with 91% content as the highest 
with the lack of trust having 17.4% as the lowest. On total reasons, less information and 
knowledge accounted for 10.2% of reasons by parents with media and internet having 2% 
(table 4). 







1.Safety and side effects: Unsafe, untested, distrust in vaccine due to 
side effects, unknown adverse effects, the concern of lasting health 
problem, not enough data, fear for adverse events. 
6. Doubts on HPV vaccine: The new vaccine, never heard of it, not 
popular, not so many are vaccinated, still deciding. 
7. No trust in drug: Don’t believe in the drug/ vaccination, no 
confidence, mistrust in drug. 






5. Other methods: She is abstaining, other methods will do, regular pap 
smear, safe sex preferred, an alternative medical approach not vaccines. 
8. Vaccine not necessary: Not needed, inconvenient, not compulsory. 
14. HPV vaccine will encourage/ increase sex: Concern over 
inappropriate sexual behaviour & unsafe sex. 
19. Difficulty in obtaining services: Vaccine not available, no access, 
any time, no provider, could not make it on time, individual freedom 
threat, long queue, distance. 
22.05% 
3 Girl child  
Related 
reasons 
2. Daughter/ girl/child age: Too young, not appropriate age, wait until 
an older age, prefer to wait until an older age, not the right time. 
3. Daughter  sexually active/non-active: Not yet having sex, already 
having a boyfriend, no boyfriend yet, she is abstaining, 
4. Daughter decide: She will make her decision; she will decide on her 
own; I respect adolescent opinion, 





12. Less information and knowledge: Need more information, lack 







Quoted responses in Safety and side effects concerns included: Unsafe, untested, distrust in 
vaccine based on side effects and unknown adverse effects. There was reported concern of 
unknown lasting future health problem, not enough data and fear of adverse events in future. 
Safety and side effects accounted for 11.98% of parental responses. Doubts on HPV vaccine, 
no trust in the drug and doubt on the effectiveness of the drug represented 6.23%, 6.03% and 
3.91% of responses. Parents claimed that they did not vaccinate their daughters because the 
vaccine was new, never heard of it, not popular, not so many are vaccinated, and some were 
still deciding. Some reported that they don’t believe in the drug or vaccination, any 
confidence, mistrust in drug, objects of research, and they felt more research was needed on 
HPV vaccine. Vaccine-related responses accounted for a total of 28.15% of the responses 
after a combination of responses. 
Parental factors, concerns and perception. 
In the data, 11.96% of responses indicated that the vaccine was not necessary, inconvenient 
and not compulsory for schooling system.  Difficulty in obtaining services, Vaccine not 
available, no access, no time, no provider, parents could not make it on time, individual 
freedom threat, long queue and distance had 4.69% response. Other methods, low risk and 
parental concern over the outcome of vaccination had 2.5%, 2.02% and 0.88% responses. 
The reasons given included; she is abstaining, other methods will are better, regular Pap 
smear, safe sex preferred and alternative medical approach, not vaccine. Parents considered 
daughter to be of low perception risk, infection not common, HPV vaccine will encourage 





13. Advised against, no visit or no recommendation. 
Told to wait, no vaccine, missed opportunity from General Practioner 
(GP) Nurse, pediatrician, gynecologist, family member, friends and 
health facility. 
16. Other medical conditions: Contra-indicated, special needs 







10. Cost related: No insurance, too expensive, not covered by insurance. 
18. Lack of trust in: Government, pharmaceutical companies. Don’t trust 






17. Religion and family decision roles in deciding: Religion/orthodox 
opposes, against family beliefs, cultural and religious values. 
20. Media and internet influence: Information read online, peer and 




Girl child-related reasons. 
Data indicated that 7.96% of responses from the parents gave reasons related to their 
daughter’s active or no active sexual activity. The reasons were: Not yet having sex, already 
having a boyfriend, no boyfriend yet and she is abstaining. Girl child age concern reasons 
were; too young, not appropriate age, need to wait until an older age and not the right time 
signifying 5.41% of responses. Fear of injections, too many injections or needles, needle 
phobia and its scaring had 3.46% of the total responses. Less than 0.44% of total responses 
indicated that parents felt that she will make her decision, she will decide on her own, and I 
respect the adolescent opinion. Combined responses had a perfect representation of 17.67%. 
General factors. 
The highest single response reported as less information and lack of knowledge on HPV 
vaccination. This accounted for 15.22% of the responses as to why parents did not vaccinate 
their daughters against HPV. The information they had was discordant, inadequate and 
scarce with the reported luck of health promotion details. This was 10.2% of total reasons for 
78.2% of primary data sources and parents wanted more information.  
Health provider factors. 
The General Practioner (GP), nurse, pediatrician, gynecologist, family member, friends and 
health facility contributed to a parental decision as expressed through reasons given. The 
reasons from the data includeadvice not to vaccinate, told to wait, no vaccine, missed 
opportunity from first encounter and no recommendation given by the health providers in 
10.38% of responses. Medical conditions, special needs children, sickness and vaccine 
contraindications had 1.03% responses. The combined factors added to 11.21% of 
responses. 
Pharmaceutical and government related reasons. 
Overall 2.91% of responses were attributed to cost. The reasons given as cost related 
included no insurance, too expensive and not covered by insurance. Data indicated that 
0.12% of all responses were due to lack of trust, combination of 3.3% of responses. There 
was reported lack of trust in government; pharmaceutical companies, public health, previous 
vaccine mistrust and feeling from parents of pressured to make the decision. 
Social media and religious reasons. 
A total of 1.84% responses indicated media and internet influence in a decision against 
vaccination. The quoted reasons were Information read online, peer and media influence, bad 
publicity and media reports. Approximately 0.97% of responses had religion and family 
decision roles considered in deciding not to vaccinate their daughters against HPV. Data 
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reasons were named as religion orthodox opposes, against family beliefs, cultural and 
religious values influencing the decision. This combination of factors contributed to 2.81% of 














































5.0 DISCUSSION   
Qualitative and Quantitative Data Results.  
According to Qualitative Met-analysis’s based on Sandelowski, both qualitative and 
quantitative primary data was combined to give the study its size effect (59). However the 
two methods used in primary articles were compared to identify similarities and differences.  
One of the major reasons expressed by parents in qualitative research articles was safety and 
side effects concern which was quoted in 90% (9/10) primary articles. In quantitative data 
sources, more articles quoted  advise against vaccination by health personnel, friends and 
luck of visit as a major reason (13/13) representing 100% against HPV vaccination. The 
least expressed reason for the decline according to qualitative research articles was a low 
risk of cervical cancer and doubt on effectiveness which both had only one article 
representing 10%. Other medical conditions, lack of trust in government and 
pharmaceuticals had one qualitative article with reasons for the decline.  
Media concern and internet reasons were least expressed in quantitative articles (1/13). 
According to this review all findings that did not express trust in the drug were qualitative. 
None of quatitative primary source expressed lack of trust in the drug. Safety and side 
effects had the highest number of articles of 21 (qualitative 9, 12 quantitative). Less 
information and knowledge had total of 18 primary sources (7 qualitative, 11 quantitative). 
Advice against HPV vaccination had total of 19 articles (6 qualitative, 13 quantitative 
sources). This research clearly indicates that both qualitative and quantitative articles had 
more similarities than differences on parental responses. The results suggest both 
methodologies had similar outcomes despite their different approach. The notable difference 
was the quantity of respondents with quantitative research having a higher sample size 
compared to qualitative methods. The researcher noted that most (19/20) of the quantitative 
‘what’ question was supported by qualitative ‘why’ responses as all the initial twenty 
similar findings consisted of both quantitative and qualitative results. It was further noted 
that only qualitative articles gave the reasons to why parents delayed vaccination based on 
no trust in the drug which was not mentioned in all quantitative articles. Twenty one 
research articles out of twenty three indicated safety concern as a major reason why parents 





5.1 DISCUSION-QUALITATIVE METASUMMARY RESULTS 
High-income nations grouped as OECD have several challenges to low HPV vaccination 
since it was licensed.  
Vaccine-related responses 
This systematic review categorized parental decisions into seven major findings as main 
explanations supporting the data on low HPV vaccination in OECD nations. Homogenized 
pooled results indicated 28.15% of responses were vaccine-related factors as primary reasons 
for not vaccinating their girl child with HPV vaccine. 
 It was represented by 28.15% of all responses explaining why they took the decision not to 
vaccinate. Their shared experiences were based on safety, Unsafe and untested HPV vaccine 
and distrust in vaccine based on side effects. They believed that the vaccine had unknown 
adverse effects and associated long lasting future problem. Their decision was based on 
belief and experience that HPV vaccine does not have enough data and due to this, there is 
fear of future adverse events. HPV vaccine as reported by the parents of non-vaccinated 
daughters is mistrusted with some parents who do not believe in the vaccine. The low 
confidence in the HPV vaccination was based on belief that their daughters are objects of 
research and they felt that more research needed on this vaccine. Other published articles 
expressed more doubts on claim of safety with vaccine adverse event reporting system 
higher than recommended (60). At the moment there is less systematic metasummary 
review highlighting this finding. According to Neural Dynamics Research Group 
publication, a list of severe adverse reactions to HPV vaccination with reported unknown 
vaccine benefits  were reported (60). 
Parental factors attributed to non-vaccination. 
Globally it's claimed the HPV vaccine risks remain unknown with its benefits still doubtful 
to the vaccinated population as protection is believed to be 70% for those immunized and 
the remaining 30% non-protection unsure (60). According to European center for disease 
control (ECDC), there has been doubting on period protection span according to randomized 
control studies were done with suggestions of a booster vaccine needed after nine years. 
Developed nations had 35 000 death in 2012 out from total death of 266 000 from cervical 
cancer. (8). The current data indicates that developed countries have few cervical cancer-
related death believed to be due to early screening success and not vaccination. This review 
result indicates parents thought the vaccine is not necessary, and it was inconveniencing 
them (11). The claim by parents that the vaccine was not available, they did not have time, 
the queue was long, there was no provider, and they were busy indicates their priorities. 
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They believed that the vaccine was not a necessity, not compulsory for school and it’s an 
inconvenience to them. It’s still unknown if more effort by parents could have changed 
parental decision leading to more acceptance to HPV vaccination. This research finding of 
parental feeling that HPV vaccine will encourage inappropriate and unsafe sex has similar 
results with a systematic review done in the USA among adolescents (61). Abstinence, safe 
sex and male circumcision among the religious group were some of the reasons given by 
parents for making HPV and cervical cancer at lower risk. This preference collaborates with 
other findings which preferred screening as the best preventive method than HPV 
vaccination (62) 
Girl child-related reasons. 
Mothers were protective in responses towards their daughters with genuine concerns that 
need to be addressed. The age factor and the number of injections totaling to 3 recommended 
at 0, 1, and six-month schedule at ages 9-12 was a limitation to some parents (63). The 
feeling of their daughter being too young and fragile, no boyfriend yet, not the right time, 
too many and fearful injections made parents feel that the girl child will make her decision 
at a later age (61). This barrier was expressed in the previous systematic review and the 
review found out older girls are likely to be vaccinated than younger age and this review 
suggests an increased flexible age can increase coverage. 
General factors 
HPV vaccination results were characterized by lack of information and knowledge by the 
parents.  This review identified inconsistent, inadequate, scarce and non-available 
information on HPV vaccine as a primary single most factor as to why parents did not 
vaccinate their daughters. Itwas indicated by 15.22% of the responses who gave the reason 
for their decision. The service provider’s knowledge about vaccination was not shared with 
the parents at satisfaction level to enable them to make a decision. These study findings agree 
with the previous review which stated that health care provider messages are often not 
delivered in a way that is clearly and easily understood by young women. It could have been 
central in explaining experiences on the lack of information on HPV vaccine (64). The most 
convenient method of administering HPV vaccine is through school-based systems, 
pediatrics clinic, and health facility or at GP clinic as indicated by the primary data. The 
information relayed from providers is given directly or through children to parents before 
decisions made. HealthProviders and parents do not have enough time to share all 
information on HPV vaccination as communication using pamphlets and printouts do not 
convince the parents to make a decision. The different, inadequate or scarce details with 
34 
 
reported lack of health promotion details contribute to delay or decline of HPV vaccination. 
Research in the USA suggested ways of reducing the barriers brought by information gap 
with a triage communication. A parent, health provider and institutions triangle will be 
essential in providing information and knowledge leading to more acceptances (65). 
Health provider factors. 
Health providers play a significant role in HPV vaccine delivery to children, and their 
decision is central to enabling parents to accept or reject the vaccine. Healthcare system 
depends centrally on providers recommendations on service uptake. A recommendation not 
to vaccinate, wait for some time, child’s current condition does not allow vaccination made 
parents delay or refuse their daughters to be vaccinated. Previous systematic reviews reported 
missed opportunity to be one of the barrier to HPV vaccination (61). Healthcare providers 
did not recommend HPV vaccination to parents during their routine visit leading parents to 
opt out. A change in message delivery system and communication mechanism between the 
parents and health providers could improve the acceptance while limiting missed an 
opportunity (61). Expert views on HPV vaccination barriers indicate that Health care 
provider communication is vital, and the results are encouraging. Where early and well-
orchestrated communication is achieved, more parents seemed to accept the vaccine for their 
daughters (66).  Primary prevention mechanism will be better if the parents can be 
empowered so that they can request for the service in places where health provider does not 
initiate. Public health promotion can be vital in giving information to the parents in advance. 
More detailed information compared to the shorter period communication between the health 
provider and the parent will empower the parent to initiate the process.  
Pharmaceutical and government related reasons. 
This review had more primary data from the USA than the rest of OECD nations. The health 
system funding has variations, and most developed countries have either tax paid healthcare 
system or government insurance. Tax paid to finance involves service provision to the 
populations with all costs incurred through citizen’s tax payment. The USA has a mixed 
system of private funding and health insurance accounting for a larger coverage.  Medicare, 
which is government financed has been improving slowly, and more Americans are getting a 
medical cover (67). A systematic review in the USA indicated that HPV vaccination cost and 
lack of insurance coverage are noted.  The estimated cost per dose is $350; the vaccine is 
expensive, and some parents do not have insurance. It will be better for subsidies or full 
government funding to enable the non-insured population to have access (64, 68). 
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According to published articles marketing strategy for the vaccine, Gardasil had Merck 
(manufacturer) funded educational programmes. The professional medical associations 
(PMAs) was usedas a marketing strategy to promote the use of their vaccine(69). Whether 
parents considered this as a factor in being pushed to accept the vaccine is unknown. The 
linkage between manufacturers, lobbying and government interest remains unexplained in 
understanding parental decisions.  Independent educators with no vested interest should be 
giving the information on the significance of HPV vaccination. Providers agree that HPV 
alone will not prevent cervical cancer and screening is needed too.  
Social media and religious reasons.  
Current social media and traffic online combined with religious beliefs influences parental 
decision making. Media reports in the USA and Japan were reported to have affected HPV 
vaccination. This review had an objective to ascertain whether the decision to reject or delay 
HPV vaccination by the parent depended majorly on social media and religion dependent 
reasons. Anti-vaccine websites and the media have been considered a smaller contributing 
factor in the parental decline to HPV vaccination. In Japan, the suspension of the official 
recommendation for the vaccine was due to reported side effects. A study done after 
negative media news indicated discontinuation among those on the vaccine (29). The effects 
of the information vacuum filled in by media speculations and non-verified sources might 
have an impact on responses accounting for 2.81% which was the least of all factors. The 
media news from Japan had more impact on nation’s vaccination. Research done by 
obstetrics and gynecologists indicated that none of their daughters were vaccinated after the 
news on reported side effects. If health providers are not willing to accept their daughters to 
be vaccinated after reported negative news, the general public has no reason to take the 
vaccine (70). A more consultative decision with all stakeholders and concerned parties with 
evidence-based reasons are needed to face negative media coverage while encouraging HPV 
vaccination. Religious beliefs was a less contributing factor to the rejection of HPV 
vaccination as noted with results. 
5.2 STRENGTH AND WEAKNESSES OF THIS STUDY. 
This study was heterogeneous as combined both quantitative and qualitative primary data 
sources as opposed to other systematic reviews. This review had a large number of findings 
with 31740 responses given to 246 reasons which was good for broad synthesis. Most 
grouped similar findings had quantitative and qualitative articles which responded to ‘what’ 
and ‘why’ component as the questionnaires had responses in interviews. The size effect 
through abstraction was met after grouping of findings. This Qualitative meta-summary 
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enabled the reviewer to assess the impact of individual primary reports and findings on 
synthesis results. High-income OECD members covering over 34 countries gave an 
extensive coverage facilitating further research inferences reaching a wider audience. The 
cost of HPV vaccine is known to be high, and affordability is a major factor in developing 
nations.  This study concentrated on high-income countries looking at factors beyond cost as 
reported by tax and insurance-based funding of HPV vaccine. The review contacted external 
individuals to give credibility while limiting bias. The publication period from January 2009 
to January 2016 was after licensure of Gardasil, which occurred in 2006. This review 
concentrated only on parents who girls had aged 9-18 who had not been vaccinated as 
required by voluntary vaccination programs. By including the grey literature and thesis 
articles during the review, the research work avoided publication bias. The author utilized 
references from other systematic reviews in broadening the data sources. Primary articles 
with raised questions were re-evaluated, and Telephone and email contacted the authors. 
There were written clarifications strengthened the study.  
Primary data sources were considered based on a parental decision on vaccination, delay or 
refusal of HPV vaccine. Most of the collected data did not verify or validate whether the 
parental choice of declining was true or false. It was based on trust as expressed by 
respondents. The majority of data source was done in the USA representing 60% of the 
articles representing abias towards one source. This research was centered on parents of 
daughters aged 10-18 as the population of interest. The parental responses were impartial as 
pharmaceutical companies, government and health provider’s responses were not considered. 
Some articles from OECD nations were not considered based on luck of HPV vaccination 
policy creating more bias. The author noted that although different countries were presented 
through primary article, this research could not verify all the 34 countries health systems as 
they are diverse with some having no clear policy on HPV vaccination.  
Qualitative Meta-summary synthesis is reflection of judgement made by the reviewer. There 
is no criteria set for what a finding should be and what to abstract and how similar findings 
determined. The synthesis method is relatively new with less documented research based on 
qualitative metasummary. Developed nations have different systems of health structures and 
funding mechanisms, this variance explains why parental decline in Scandinavian nations is 
less compared to the USA. Tax based funding, government insurance, private insurance and 
out of pocket payments are some of the funding mechanisms in different nations.  
More research is needed on individual country factors that are making nations like Norway 
with public funded programs with lower than 78% (15). It’s estimated that almost 9 out of 
37 
 
every 10 of cervical cancer death are from developing nations, yet the HPV vaccine is 
available, affordable and accessible to high-incomecountries.  More research is needed on 
developing country’s factors other than cost-related barriers. 
CHAPTER 6 
6.0 CONCLUSION. 
Low HPV vaccination coverage is attributed to many reasons as given by different 
implementers of vaccination programs within OECD nations. The parent determines the 
decision to vaccinate at targeted age as required by regulation for the benefit of girl Childs 
future. This systematic review focused on decisions made based on several factors of which if 
addressed, the parents might change their decision and accept HPV vaccine to be administered. 
These shared and expressed responses are directed at different levels. The majority of these 
responses include vaccine-related reasons, parental factors, girl child related and general 
factors. Health provider related factors, pharmaceuticals or government, social and religious 
related factors contributed less to the parental decision to decline. Public health activities on 
cervical cancer prevention are centrally attached to parents. Providing adequate evidence-
based, transparent, and accessible information to parents about HPV infection, vaccine safety, 
adverse effects, and the appropriate age for vaccination may make health care professionals 
able to reduce concerns and misconceptions about the vaccine. The researcher believes a well 
organized health promotion strategy directed at each group with suitable monitoring 
mechanisms will provide the best solution in developed countries.  The researcher of this 
review concludes that these parental explained reasons if addressed through collective 
measures by primary public or private health prevention players will decrease refusal and 
increase HPV vaccination coverage. Further research is required in assessing immunity of 
vaccinated and non-vaccinated groups to ascertain the protection difference by measuring 












Appendix 1. Data and findings Extraction Template for Qualitative Evidence 
Finding  
Illustrations from publication 
(including page number) 
 
Evidence Unequivocal 

























Data analysis  







Appendix 2: STANFORD UNIVERSITY APPRAISAL TOOL. 
APPRAISAL TOOL FOR CROSS-SECTIONAL RESEARCH. 
 Cross-sectional Study Section P: Brief Summary of Paper:  












Primary source of data: 
 
Follow-up subsequent to cross-sectional study:             [ ] Yes                                  [ ] No 
Number considered for enrolment: 
 
Enrolled Number enrolled: 
 




Other relevant information: 
Sections P-R: Cross-sectional Study 
Section Q: Specific methodological issues 
(Y= Yes, S= substandard, NC= Not Clear, NR= Not Reported,  N=NO,NA= Not 
Applicable, NQ= Not Qualified to Assess); cite apage number for key comments. 
 
CRITERIA Y S N NC  NR NA NQ comments 
Similar sampling procedures for all subjects         
Similar ascertainment of exposure for all subjects         
Similar referral and diagnostic procedures for all 
subjects 
        
Diagnostic criteria for diseased clear, precise, 
and valid 
        
Characteristics of subjects at enrolment.         
All aspects of exposure measured (level, dose, 
duration) 
        
Co-exposure measured         
Recall bias controlled         
Data collection valid and reliable         











Section S Conclusions and assessment of the article 
i. Strengths of the paper 
 
ii. Weaknesses of the paper 
 
iii. Reviewer’s conclusions (if different from authors) 
 
iv. Clinical relevance. 
                  Highly relevant                                                  [ ] 
                  Relevant                                                             [ ] 
                  Questionable relevance                                      [ ] 
                  Irrelevant                                                            [ ] 
                 Not qualified to evaluate                                     [ ] 
 
v. Scientific merit 
              Very good                                                               [ ] 
              Good                                                                       [ ] 
              Scientifically admissible                                         [ ] 
              Scientifically inadmissible                                      [ ] 
Section S: Conclusions assessment of the article 
vi. The Type of study: 
Randomized controlled trial conducted & interpreted correctly                                     [ ] 
Controlled trial with evidence of comparability of groups                                             [ ] 
Well-designed cohort or case-control study                                                                    [ ] 
Case series or cohort study without controls                                                                   [ ] 
Opinions of competent authorities based on clinical experience, descriptive studies, research, 
or studies not classified in the preceding categories                                                             [ ] 
Other, including substandard of the above                                                                            [ ] 
 
vii. Recommendations concerning possible additional specialized reviewer 
 











Appendix 3 risk of bias assessment tool for quantitative research. 
 














Were participants analysed within the groups they were 
originally assigned to? 
x  
Did the study apply inclusion/exclusion criteria uniformly 
to all comparison groups? 
X x 
Did strategy for recruiting participants into the study differ 
across study groups? 
x  
Does the design or analysis control account for important 
confounding and modifying variables through matching, 





the researchers rule outon impact from  intervention or  
unintended exposure  which can give biased outcome? 
X x 
Has study maintain fidelity to the intervention protocol? x  
Attrition bias If attrition (overall or differential non-response, dropout, 
loss , or exclusion of participants) was a concern, were 
missing data handled appropriately (e.g., intention-to-treat 




In prospective studies, was the length of follow-up different 
between the groups, or in case-control studies, was the time 
period between the intervention/exposure and outcome the 
same for cases and controls? 
x  
Were the outcome assessors blinded to the intervention or 
exposure status of participants? 
x x 
Were interventions/exposures assessed/defined using valid 
and reliable measures, implemented consistently across all 
study participants? 
x x 
Were outcomes assessed/defined using valid and reliable 
measures, implemented consistently across all study 
participants? 
x x 
Were confounding variables assessed using valid and 





Were the potential outcomes pre-specified by the 
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